High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor

Circulation

Volumn 98, Issue 21, 1998, Pages 2241-2247

  Thögersen, Anna M ^a   Jansson, Jan Håkan ^b   Boman, Kurt ^b   Nilsson, Torbjörn K ^a   Weinehall, Lars ^c   Huhtasaari, Fritz ^d   Hallmans, Göran ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Skellefteå County Hospital   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d Luleå Hospital   (Sweden)

Author keywords

Myocardial infarction; Plasminogen activators; Risk factors; Von Willebrand factor

Indexed keywords

APOLIPOPROTEIN A1; PLASMINOGEN ACTIVATOR INHIBITOR; PRASTERONE SULFATE; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY; RISK FACTOR;

EID: 0032564442     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.21.2241     Document Type: Article

References (12)

1. Nyström L, Rosén M, Wall S. Why are diabetes, stomach cancer, and circulatory diseases more common in Northern Sweden? Scand J Prim Health Care 1986;4:5-12.
2. Heller RF, Chinn S, Tunnstall Pedoe HD, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Prevention Project. Br Med J. 1984;288:1409-1411.
3. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals: AHA Medical/Scientific Statement Advisory. Circulation. 1991;83:356-362.
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
5. Hamsten A. The hemostatic system and coronary heart disease. Thromb Res. I993;70:1-38.
6. Lijnen HR, Collen D. Impaired fibrinolysis and the risk for coronary heart disease. Circulation. 1996;94:2052-2054.
7. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet. 1993;341:1165-1168.
8. Thögersen AM, Boman K, Hallmans G, Huhtasaari F, Jansson J-H, Nilsson TK, Weinehall L. Höga plasmakoncentrationer av plasminogen activator inhibitor (PAI-1) och tissue plasminogen activator (tPA) är riskfaktorer för förstegångsinfarkt både hos mäh och kvinnor (in Swedish). Svenska Läkaresällskapets Riksslämma. November 26-28, 1997;CA7:135. Abstract.
9. Weinehall L, Johnson O, Jansson JH, Boman K, Huhtasaari F, Hallmans G, Dahlen GH, Wall S. Perceived health modifies the effect of biomedical risk factors in the prediction of acute myocardial infarction. An incident case-control study from northern Sweden. J Intern Med. 1998;243:99-107.
10. Huhtasaari F, Asplund K, Wester PO. Cardiovascular risk factors in the northern Sweden MONICA Study. Acta Med Scand. 1988;224:99-108.
11. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A, for the WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583-612.
12. Rånby M, Bergsdorf N, Nilsson TK, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem. 1986;32:2160-2165.